ENHANCE- Establishing Natural History in an Advanced New CF Care Era

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

550 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-31

Study Completion Date

2028-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Measured outcomes for people with CF have improved dramatically over the last 20 years, even prior to the widespread introduction of cystic fibrosis transmembrane conductance regulator (CTFR) modulator treatments. The outlook for children with CF has improved significantly, with longer predicted survival and a lower likelihood of morbidity. This has accelerated recently. These changes have occurred within a short period of time, and there is much that we now do not understand about disease progression in children with CF and how this differs from children without CF. CF is an area which is fortunate to have well-developed and successful disease registries. CF registries have provided significant amounts of very useful data to guide improvement in treatment and outcomes over many decades. The power of registries comes from the collection of a well-defined set of important outcome measures in very large numbers of people over many years.

The outcome measures collected routinely in clinical care, which form part of the registries, are helpful in monitoring moderate-advances and symptomatic disease in people with CF. CF registries however do not tend to collect tomography(CT) scores, lung clearance index(LCI) or indeed repeated collection of biomarkers of disease activity such as sweat chloride which are increasingly relevant in an era of modulator therapies and reducing burden of symptomatic disease. We perceive an urgent need to complement registry data, cataloguing the changing natural history if early childhood CF by proactively collecting and curating sensitive, meaningful outcome data in a large cohort of children during this new era in Ireland and the UK.

The prevalence, presentation and natural history of disease manifestation of CF in young children will change significantly in the next decade with advances in the understanding and treatment of CF, including the use of therapies aimed at CFTR function. ENHANCE provides an opportunity to study these changes in real-time and in ways that are relevant to the CF community.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Home Monitoring to Predict Exacerbation in Cystic Fibrosis

NCT02416375

Cystic Fibrosis

COMPLETED

Health Outcomes of Parents With Cystic Fibrosis-Aim 2

NCT06296394

Cystic Fibrosis Parenthood Status

RECRUITING

Evaluation of the Evolution of Quality of Life in Relation to Naso-sinus Symptomatology Under Treatment With CFTE Modulators in Children Aged 6 to 11 Years With Cystic Fibrosis With Compatible Mutation

NCT05581056

Cystic Fibrosis

COMPLETED

Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients

NCT02965326

Cystic Fibrosis

RECRUITING NA

Continuous Cardiorespiratory Monitoring in Cystic Fibrosis

NCT04489186

Cystic Fibrosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Newborn infants diagnosed with Cystic Fibrosis at newborn screening

Quality of Life

Intervention Type OTHER

ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period

Cohort 2

Children with previous diagnosis of Cystic Fibrosis up to 5 years of age

Quality of Life

Intervention Type OTHER

ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period

Control

Newborn infants without cystic fibrosis

Quality of Life

Intervention Type OTHER

ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quality of Life

ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Children with CF attending one of the study centres and fulling one of the following:

* Newborn infant diagnoses with cystic fibrosis through newborn screening (excludes children with an uncertain diagnosis), or having 2 documented CF disease causing mutations.
* Children with CF (sweat chloride\>60mmol/L or 2 CF disease causing mutations) aged 0-6 at study initiation
* Healthy control infants without CF

Exclusion Criteria

* Children or their parents not willing or able to complete with study procedures or assessments.
* Co-morbidities in groups 1 and 2, unrelated to CF, that in the opinion of the investigator would substantially impact on study measurements and unduly affect the veracity of the outcome data, for example a diagnosis of inflammatory bowel disease or extreme prematurity.
* Children in the control group who are carriers of CFTR mutations or have chronic medical or GI/Liver conditions that in the opinion of the investigator would unduly affect the veracity of the outcome data.
* We will not exclude someone who subsequently joins a CF Investigational drug trial if they are happy to continue, but if possible, will time their annual ENHANCE data collection to fall outside the time period of any experimental study drug administration

Minimum Eligible Age

1 Month

Maximum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes